Allergy/Immunology

Top Story

Compound interest: A powerful ancillary revenue stream

Compound interest: A powerful ancillary revenue stream
February 12, 2020

Azar: HHS ‘should be very proud’ of its achievements, life expectancy among them

February 7, 2020
The past 3 years were marked by historic accomplishments that put HHS in a strong position to tackle the challenges that lie ahead, HHS Secretary Alex Azar II
Feature

Single-center study raises larger issues about proper billing

February 4, 2020
Two CMS codes for advanced care planning — 99497 and 99498 — were used less than 20 times at a tertiary care center in Iowa during in a nearly 3-year period…
FDA News

FDA, Federal Trade Commission to target 'anti-competitive' practices to support biosimilars

February 3, 2020
The FDA and the Federal Trade Commission on Monday announced a partnership aimed at supporting the adoption of biosimilars and interchangeable products by deterring what…
FDA News

FDA approves Palforzia, first peanut allergy treatment for children

February 3, 2020
The FDA announced that it approved the oral immunotherapy Palforzia, the first treatment for peanut allergy in children aged 4 to 17 years. According to the FDA and the…
More Headlines »